These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36053786)

  • 1. Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
    Abramson JS; Bengston E; Redd R; Barnes JA; Takvorian T; Sokol L; Lansigan F; Armand P; Shah B; Jacobsen E; Martignetti R; Turba E; Metzler S; Patterson V; LaCasce AS; Bello CM
    Blood Adv; 2023 Apr; 7(7):1130-1136. PubMed ID: 36053786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
    Abramson JS; Arnason JE; LaCasce AS; Redd R; Barnes JA; Sokol L; Joyce R; Avigan D; Neuberg D; Takvorian RW; Hochberg EP; Bello CM
    Blood; 2019 Aug; 134(7):606-613. PubMed ID: 31186274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
    Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
    Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
    Ramchandren R; Advani RH; Ansell SM; Bartlett NL; Chen R; Connors JM; Feldman T; Forero-Torres A; Friedberg JW; Gopal AK; Gordon LI; Kuruvilla J; Savage KJ; Younes A; Engley G; Manley TJ; Fenton K; Straus DJ
    Clin Cancer Res; 2019 Mar; 25(6):1718-1726. PubMed ID: 30617130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
    Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
    Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
    Ansell SM; Radford J; Connors JM; Długosz-Danecka M; Kim WS; Gallamini A; Ramchandren R; Friedberg JW; Advani R; Hutchings M; Evens AM; Smolewski P; Savage KJ; Bartlett NL; Eom HS; Abramson JS; Dong C; Campana F; Fenton K; Puhlmann M; Straus DJ;
    N Engl J Med; 2022 Jul; 387(4):310-320. PubMed ID: 35830649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
    Fornecker LM; Lazarovici J; Aurer I; Casasnovas RO; Gac AC; Bonnet C; Bouabdallah K; Feugier P; Specht L; Molina L; Touati M; Borel C; Stamatoullas A; Nicolas-Virelizier E; Pascal L; Lugtenburg P; Di Renzo N; Vander Borght T; Traverse-Glehen A; Dartigues P; Hutchings M; Versari A; Meignan M; Federico M; André M;
    J Clin Oncol; 2023 Jan; 41(2):327-335. PubMed ID: 35867960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
    Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
    N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
    Kumar A; Casulo C; Yahalom J; Schöder H; Barr PM; Caron P; Chiu A; Constine LS; Drullinsky P; Friedberg JW; Gerecitano JF; Hamilton A; Hamlin PA; Horwitz SM; Jacob AG; Matasar MJ; McArthur GN; McCall SJ; Moskowitz AJ; Noy A; Palomba ML; Portlock CS; Straus DJ; VanderEls N; Verwys SL; Yang J; Younes A; Zelenetz AD; Zhang Z; Moskowitz CH
    Blood; 2016 Sep; 128(11):1458-64. PubMed ID: 27458003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
    Hutchings M; Radford J; Ansell SM; Illés Á; Sureda A; Connors JM; Sýkorová A; Shibayama H; Abramson JS; Chua NS; Friedberg JW; Kořen J; LaCasce AS; Molina L; Engley G; Fenton K; Jolin H; Liu R; Gautam A; Gallamini A
    Hematol Oncol; 2021 Apr; 39(2):185-195. PubMed ID: 33462822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.
    Herrera AF; LeBlanc M; Castellino SM; Li H; Rutherford SC; Evens AM; Davison K; Punnett A; Parsons SK; Ahmed S; Casulo C; Bartlett NL; Tuscano JM; Mei MG; Hess BT; Jacobs R; Saeed H; Torka P; Hu B; Moskowitz C; Kaur S; Goyal G; Forlenza C; Doan A; Lamble A; Kumar P; Chowdhury S; Brinker B; Sharma N; Singh A; Blum KA; Perry AM; Kovach A; Hodgson D; Constine LS; Shields LK; Prica A; Dillon H; Little RF; Shipp MA; Crump M; Kahl B; Leonard JP; Smith SM; Song JY; Kelly KM; Friedberg JW
    N Engl J Med; 2024 Oct; 391(15):1379-1389. PubMed ID: 39413375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study.
    Evens AM; Connors JM; Younes A; Ansell SM; Kim WS; Radford J; Feldman T; Tuscano J; Savage KJ; Oki Y; Grigg A; Pocock C; Dlugosz-Danecka M; Fenton K; Forero-Torres A; Liu R; Jolin H; Gautam A; Gallamini A
    Haematologica; 2022 May; 107(5):1086-1094. PubMed ID: 34162178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.
    Evens AM; Advani RH; Helenowski IB; Fanale M; Smith SM; Jovanovic BD; Bociek GR; Klein AK; Winter JN; Gordon LI; Hamlin PA
    J Clin Oncol; 2018 Oct; 36(30):3015-3022. PubMed ID: 30179569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma.
    Park SI; Shea TC; Olajide O; Reddy NM; Budde LE; Ghosh N; Deal AM; Noe JF; Ansell SM
    Blood Adv; 2020 Jun; 4(11):2548-2555. PubMed ID: 32516414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
    Kumar A; Casulo C; Advani RH; Budde E; Barr PM; Batlevi CL; Caron P; Constine LS; Dandapani SV; Drill E; Drullinsky P; Friedberg JW; Grieve C; Hamilton A; Hamlin PA; Hoppe RT; Horwitz SM; Joseph A; Khan N; Laraque L; Matasar MJ; Moskowitz AJ; Noy A; Palomba ML; Schöder H; Straus DJ; Vemuri S; Yang J; Younes A; Zelenetz AD; Yahalom J; Moskowitz CH
    J Clin Oncol; 2021 Jul; 39(20):2257-2265. PubMed ID: 33909449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].
    Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T
    Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
    Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
    Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
    Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ;
    Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
    Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
    Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.